KINDERHOOK, N.Y. – May 15, 2014 – American Bio Medica Corporation (OTCQB:ABMC) today announced financial results for the three months ended March 31, 2014.

Net sales for the first quarter of 2014 were $2,043,000, a decrease of $82,000, or 3.8%, when compared to net sales of $2,125,000 for the first quarter of 2013. Operating income for the first quarter of 2014 was $62,000, compared to an operating loss of $362,000 in the first quarter of 2013. Net income for the first quarter of 2014 was $9,000, or $0.00 per share, compared to a net loss of $424,000, or $0.02 per share reported in the first quarter of 2013.

ABMC Interim Chief Executive Officer Melissa A. Waterhouse stated, “I am pleased to report our first quarter of net income for the first time in many years. From a sales perspective, organic growth partially offset the loss of oral fluid workplace sales in the first quarter 2014. Typically workplace oral fluid sales accounted for approximately 15% of our sales, but sales only declined 3.8% in the first quarter 2014. This is a result of our refocus on forensic oral fluid sales and sales of our urine-based products to other core markets.”

Waterhouse continued, “Expenses are under control and we are continuing to take actions to bring a new urine-based drug test to market; this new product will be ideal for the clinical and pain management markets, as well as the criminal justice market. Strategic opportunities are still being considered and evaluated; this includes a possible restructure of debt which could further strengthen our financial condition.”

For more information on ABMC or its drug testing products, please visit

About American Bio Medica Corporation

American Bio Medica Corporation develops, manufactures and markets accurate, cost-effective immunoassay test kits, primarily point of collection tests for drugs of abuse. The Company and its worldwide distribution network target the workplace, government, corrections, clinical and educational markets. ABMC’s Rapid Drug Screen®, Rapid ONE®, RDS® InCup®, Rapid TOX® and Rapid TOX Cup® II test for the presence or absence of drugs of abuse in urine, while OralStat® and Rapid STAT™ test for the presence or absence of drugs of abuse in oral fluids. ABMC’s Rapid Reader® is a compact, portable device that, when connected to any computer, interprets the results of an ABMC drug screen, and sends the results to a data management system, enabling the test administrator to easily manage their drug testing program.

This release may contain forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause actual results to differ, and such differences could be material. Such risks and uncertainties include, but are not limited to, risks and uncertainties related to the following: continued acceptance of our products, increased levels of competition in our industry, acceptance of new products, product development, compliance with regulatory requirements, intellectual property rights, our dependence on key personnel, third party sales and suppliers, trading in our common shares may be subject to “penny stock” rules, our history of recurring net losses and our ability to continue as a going concern. There can be no assurance that the Company will be successful in addressing such risks and uncertainties and the Company assumes no duty to update any forward-looking statements based upon actual results. Investors are strongly encouraged to review the section entitled “Risk Factors” in the Company’s annual report on Form 10-K for the year ended December 31, 2013, quarterly reports on Form 10-Q, and other periodic reports on file with the Securities and Exchange Commission for a discussion of risks and uncertainties that could affect operating results and the market price of the Company’s common shares.

Condensed Statements of Operations
For the threeFor the three
months endedmonths ended
March 31, 2014March 31, 2013
Net sales$


Cost of goods sold1,166,0001,339,000
Gross profit877,000786,000
Operating expenses:
Research and development46,00063,000
Selling and marketing292,000475,000
General and administrative477,000610,000
Total operating expenses815,0001,148,000
Operating income / (loss)62,000(362,000)
Other expense(52,000)(61,000)
Net income / (loss) before tax10,000(423,000)
Income tax expense(1,000)(1,000)
Net income / (loss)$9,000$(424,000)
Basic & diluted income / (loss) per common share$0.00$(0.02)
Weighted average shares outstanding – basic23,168,15522,166,336
Weighted average shares outstanding – diluted23,260,58222,166,336

(Condensed Balance Sheets follow)

American Bio Medica Corporation
Condensed Balance Sheets
March 31,December 31,


Current Assets
Cash and cash equivalents$521,000$646,000

Accounts receivable, net of allowance for doubtful accounts of
$52,000 at March 31, 2014 and $58,000 at December 31, 2013



Inventory, net of allowance of $399,000 at March 31, 2014 and
December 31, 2013



Current portion of deferred financing72,00051,000
Prepaid expenses and other current assets124,00096,000
Total current assets3,592,0003,739,000
Property, plant and equipment, net1,062,0001,090,000
Deferred finance costs31,00080,000
Patents, net44,00043,000
Other assets14,00014,000
Total assets$4,743,000$4,966,000
Current liabilities
Accounts payable633,000597,000
Accrued expenses and other current liabilities252,000314,000
Wages payable255,000233,000
Line of credit, net814,000987,000
Current portion of long-term debt, net1,136,0001,226,000
Total current liabilities3,090,0003,357,000
Other liabilities148,000147,000
Related party note124,000124,000
Total liabilities3,362,0003,628,000
Stockholders’ Equity:
Common stock232,000229,000
Additional paid-in capital20,272,00020,241,000
Accumulated deficit(19,123,000)(19,132,000)
Total stockholders’ equity1,381,0001,338,000
Total liabilities and stockholders’ equity$4,743,000$4,966,000
American Bio Medica Corporation
Melissa A. Waterhouse, (800) 227-1243, Ext 107
Interim Chief Executive Officer